$ cat ./records/rotavac-gates-supported-1-oral-rotavirus-vaccine-reaches-25-milli-2011.txt
ROTAVAC — Gates-Supported $1 Oral Rotavirus Vaccine Reaches 25 Million Indian Children Annually
[RECORD.TXT] · cat --full
The Gates Foundation's collaboration with PATH and Bharat Biotech International produced ROTAVAC, an oral rotavirus vaccine developed from an Indian virus strain and manufactured in India at $1 per dose — 99 percent less than the original Merck product. ROTAVAC was the first vaccine developed from a strain isolated from Indian children. India's Universal Immunisation Programme introduced ROTAVAC in 2016, delivering oral drops to an estimated 25 million infants annually and preventing an estimated 78,000 child deaths per year from rotavirus diarrhoea.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Launches Reinvent the Toilet Challenge with Over $200 Million Commitment
Next →
Gates Foundation Funds PATH to Accelerate Japanese Encephalitis Vaccine Introduction in High-Burden Regions
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.